Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
6
result(s) for
"Winnicki, Anna C"
Sort by:
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
2024
New therapeutics are necessary for preventing
Plasmodium vivax
malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. In this manuscript we characterize 12 Pv Apical Membrane Antigen 1 (PvAMA1) specific human monoclonal antibodies from Peripheral Blood Mononuclear Cells of a Pv-exposed individual. PvAMA1 is essential for sporozoite and merozoite invasion, making it a unique therapeutic target. We show that humAb 826827 blocks the invasion of human reticulocytes using Pv clinical isolates and inhibits sporozoite invasion of human hepatocytes in vitro (IC
50
of 0.3 – 3.7 µg/mL). Inoculation of human liver transgenic (FRG-humHep) female mice with humAb 826827 significantly reduces liver infection in vivo. The crystal structure of rPvAMA1 bound to 826827 shows that 826827 partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. We have isolated a potent humAb that is isolate-transcendent, blocks both pre-erythrocytic and blood stage infection, and could be a potential therapy for Pv.
Here the authors isolate monoclonal antibodies specific for
Plasmodium vivax
apical membrane antigen 1, and characterize the epitope of one antibody that inhibits invasion of reticulocytes and hepatocytes, and reduces liver infection in a mouse model.
Journal Article
Comparing new tools of artificial intelligence to the authentic intelligence of our global health students
by
Gardner, Jacob E.
,
Rao, Tharun M.
,
Moorthy, Skanda
in
Algorithms
,
Artificial intelligence
,
Bioethics
2024
Introduction
The transformative feature of Artificial Intelligence (AI) is the massive capacity for interpreting and transforming unstructured data into a coherent and meaningful context. In general, the potential that AI will alter traditional approaches to student research and its evaluation appears to be significant. With regard to research in global health, it is important for students and research experts to assess strengths and limitations of GenAI within this space. Thus, the goal of our research was to evaluate the information literacy of GenAI compared to expectations that graduate students meet in writing research papers.
Methods
After completing the course, Fundamentals of Global Health (INTH 401) at Case Western Reserve University (CWRU), Graduate students who successfully completed their required research paper were recruited to compare their original papers with a paper they generated by ChatGPT-4o using the original assignment prompt. Students also completed a Google Forms survey to evaluate different sections of the AI-generated paper (e.g., Adherence to Introduction guidelines, Presentation of three perspectives, Conclusion) and their original papers and their overall satisfaction with the AI work. The original student to ChatGPT-4o comparison also enabled evaluation of narrative elements and references.
Results
Of the 54 students who completed the required research paper, 28 (51.8%) agreed to collaborate in the comparison project. A summary of the survey responses suggested that students evaluated the AI-generated paper as inferior or similar to their own paper (overall satisfaction average = 2.39 (1.61–3.17); Likert scale: 1 to 5 with lower scores indicating inferiority). Evaluating the average individual student responses for 5 Likert item queries showed that 17 scores were < 2.9; 7 scores were between 3.0 to 3.9; 4 scores were ≥ 4.0, consistent with inferiority of the AI-generated paper. Evaluation of reference selection by ChatGPT-4o (
n
= 729 total references) showed that 54% (
n
= 396) were authentic, 46% (
n
= 333) did not exist. Of the authentic references, 26.5% (105/396) were relevant to the paper narrative; 14.4% of the 729 total references.
Discussion
Our findings reveal strengths and limitations on the potential of AI tools to assist in understanding the complexities of global health topics. Strengths mentioned by students included the ability of ChatGPT-4o to produce content very quickly and to suggest topics that they had not considered in the 3-perspective sections of their papers. Consistently presenting up-to-date facts and references, as well as further examining or summarizing the complexities of global health topics, appears to be a current limitation of ChatGPT-4o. Because ChatGPT-4o generated references from highly credible biomedical research journals that did not exist, our findings conclude that ChatGPT-4o failed an important component in using information effectively. Moreover, misrepresenting trusted sources of public health information is highly concerning, particularly given recent experiences from the COVID-19 pandemic and more recently in reporting on the impact of, and response to natural disasters. This is a significant limitation of GenAI’s ability to meet information literacy standards expected of graduate students.
Journal Article
Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
by
Malachin, Alyssa N
,
Dietrich, Melanie H
,
Redinger, Karli R
in
Antigens
,
Apical membrane antigen 1
,
Clinical isolates
2024
New therapeutics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. We isolated 12 Pv Apical Membrane Antigen 1 (PvAMA1) specific human monoclonal antibodies from Peripheral Blood Mononuclear Cells of a Pv exposed individual. PvAMA1 is essential for sporozoite and merozoite invasion, making it a unique therapeutic target. HumAb 826827 blocked the invasion of human erythrocytes using Pv clinical isolates and inhibited sporozoite invasion of human hepatocytes in vitro (IC50 of 0.3 to 3.7 ug/mL). It also significantly reduced liver infection of chimeric FRG humHep mice in vivo. The crystal structure of rPvAMA1 bound to 826827 shows that 826827 partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. We have isolated a potent humAb that is isolate transcendent, blocks both pre erythrocytic and blood stage infection, and could be a new therapy for Pv.
Journal Article
In vivo Ebola virus infection leads to a strong innate response in circulating immune cells
by
Honko, Anna N.
,
Gire, Stephen K.
,
Winnicki, Sarah M.
in
Aerosols
,
Animal Genetics and Genomics
,
Animals
2016
Background
Ebola virus is the causative agent of a severe syndrome in humans with a fatality rate that can approach 90 %. During infection, the host immune response is thought to become dysregulated, but the mechanisms through which this happens are not entirely understood. In this study, we analyze RNA sequencing data to determine the host response to Ebola virus infection in circulating immune cells.
Results
Approximately half of the 100 genes with the strongest early increases in expression were interferon-stimulated genes, such as ISG15, OAS1, IFIT2, HERC5, MX1 and DHX58. Other highly upregulated genes included cytokines CXCL11, CCL7, IL2RA, IL2R1, IL15RA, and CSF2RB, which have not been previously reported to change during Ebola virus infection. Comparing this response in two different models of exposure (intramuscular and aerosol) revealed a similar signature of infection. The strong innate response in the aerosol model was seen not only in circulating cells, but also in primary and secondary target tissues. Conversely, the innate immune response of vaccinated macaques was almost non-existent. This suggests that the innate response is a major aspect of the cellular response to Ebola virus infection in multiple tissues.
Conclusions
Ebola virus causes a severe infection in humans that is associated with high mortality. The host immune response to virus infection is thought to be an important aspect leading to severe pathology, but the components of this overactive response are not well characterized. Here, we analyzed how circulating immune cells respond to the virus and found that there is a strong innate response dependent on active virus replication. This finding is in stark contrast to in vitro evidence showing a suppression of innate immune signaling, and it suggests that the strong innate response we observe in infected animals may be an important contributor to pathogenesis.
Journal Article
Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever
2018
Lassa fever, a hemorrhagic fever caused by Lassa virus (LASV), is endemic in West Africa. It is difficult to distinguish febrile illnesses that are common in West Africa from Lassa fever based solely on a patient’s clinical presentation. The field performance of recombinant antigen-based Lassa fever immunoassays was compared to that of quantitative polymerase chain assays (qPCRs) using samples from subjects meeting the case definition of Lassa fever presenting to Kenema Government Hospital in Sierra Leone. The recombinant Lassa virus (ReLASV) enzyme-linked immunosorbant assay (ELISA) for detection of viral antigen in blood performed with 95% sensitivity and 97% specificity using a diagnostic standard that combined results of the immunoassays and qPCR. The ReLASV rapid diagnostic test (RDT), a lateral flow immunoassay based on paired monoclonal antibodies to the Josiah strain of LASV (lineage IV), performed with 90% sensitivity and 100% specificity. ReLASV immunoassays performed better than the most robust qPCR currently available, which had 82% sensitivity and 95% specificity. The performance characteristics of recombinant antigen-based Lassa virus immunoassays indicate that they can aid in the diagnosis of LASV Infection and inform the clinical management of Lassa fever patients.
Journal Article
Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients
2016
Calcineurin-inhibitors and hepatitis C virus (HCV) infection increase the risk of post-transplant diabetes mellitus. Chronic HCV infection promotes insulin resistance rather than beta-cell dysfunction. The objective was to elucidate whether a conversion from tacrolimus to cyclosporine A affects fasting and/or dynamic insulin sensitivity, insulin secretion or all in HCV-positive renal transplant recipients.
In this prospective, single-center study 10 HCV-positive renal transplant recipients underwent 2h-75g-oral glucose tolerance tests before and three months after the conversion of immunosuppression from tacrolimus to cyclosporine A. Established oral glucose tolerance test-based parameters of fasting and dynamic insulin sensitivity and insulin secretion were calculated. Data are expressed as median (IQR).
After conversion, both fasting and challenged glucose levels decreased significantly. This was mainly attributable to a significant amelioration of post-prandial dynamic glucose sensitivity as measured by the oral glucose sensitivity-index OGIS [422.17 (370.82-441.92) vs. 468.80 (414.27-488.57) mL/min/m2, p = 0.005), which also resulted in significant improvements of the disposition index (p = 0.017) and adaptation index (p = 0.017) as markers of overall glucose tolerance and beta-cell function. Fasting insulin sensitivity (p = 0.721), insulinogenic index as marker of first-phase insulin secretion [0.064 (0.032-0.106) vs. 0.083 (0.054-0.144) nmol/mmol, p = 0.093) and hepatic insulin extraction (p = 0.646) remained unaltered. No changes of plasma HCV-RNA levels (p = 0.285) or liver stiffness (hepatic fibrosis and necroinflammation, p = 0.463) were observed after the conversion of immunosuppression.
HCV-positive renal transplant recipients show significantly improved glucose-stimulated insulin sensitivity and overall glucose tolerance after conversion from tacrolimus to cyclosporine A. Considering the HCV-induced insulin resistance, HCV-positive renal transplant recipients may benefit from a cyclosporine A-based immunosuppressive regimen.
ClinicalTrials.gov NCT02108301.
Journal Article